A Study of PRT2527 in Participants With Advanced Solid Tumors
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Sarcoma|Castrate Resistant Prostate Cancer|Hormone Receptor Positive HER2 Negative Breast Cancer|Non-small Cell Lung Cancer|Solid Tumors With Known MYC Amplification
Interventions: DRUG: PRT2527
Sponsor: Prelude Therapeutics